Xilio Therapeutics logo

Xilio TherapeuticsNASDAQ: XLO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

22 October 2021

Next earnings report:

01 April 2025

Last dividends:

N/A

Next dividends:

N/A
$43.12 M
-93%vs. 3y high
33%vs. sector
-vs. 3y high
-vs. sector
-30%vs. 3y high
58%vs. sector
-51%vs. 3y high
76%vs. sector

Price

after hours | Wed, 20 Nov 2024 22:42:16 GMT
$0.98-$0.04(-3.83%)

Dividend

No data over the past 3 years
$2.26 M-$14.02 M

Analysts recommendations

Institutional Ownership

XLO Latest News

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
globenewswire.com07 November 2024 Sentiment: POSITIVE

Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab, in a late-breaker poster presentation at the SITC Annual Meeting

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D.
globenewswire.com13 June 2024 Sentiment: POSITIVE

WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Aoife Brennan, M.D., and James Shannon, M.D., to the company's board of directors.

Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
Zacks Investment Research16 April 2024 Sentiment: POSITIVE

Xilio (XLO) surges by 79.8% in just one month following the announcement of an exclusive worldwide licensing agreement with Gilead Sciences for the development of XTX301 for advanced solid tumors.

Why Is Xilio Therapeutics (XLO) Stock up 168% Today?
InvestorPlace28 March 2024 Sentiment: POSITIVE

Xilio Therapeutics (NASDAQ: XLO ) stock is rocketing higher on Thursday after the clinical-stage biotechnology company signed an exclusive license agreement with Gilead Sciences (NASDAQ: GILD ). This agreement has Gilead taking over the development and commercialization responsibilities of Xilio Therapeutics' XTX301.

Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
GlobeNewsWire31 October 2023 Sentiment: POSITIVE

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will host an investor conference call and webcast on November 6, 2023 at 8:00 a.m. ET to review progress across its pipeline of tumor-activated molecules, including Phase 1/2 clinical data for XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, which will be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, California from November 1-5, 2023.

What type of business is Xilio Therapeutics?

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

What sector is Xilio Therapeutics in?

Xilio Therapeutics is in the Healthcare sector

What industry is Xilio Therapeutics in?

Xilio Therapeutics is in the Biotechnology industry

What country is Xilio Therapeutics from?

Xilio Therapeutics is headquartered in United States

When did Xilio Therapeutics go public?

Xilio Therapeutics initial public offering (IPO) was on 22 October 2021

What is Xilio Therapeutics website?

https://xiliotx.com

Is Xilio Therapeutics in the S&P 500?

No, Xilio Therapeutics is not included in the S&P 500 index

Is Xilio Therapeutics in the NASDAQ 100?

No, Xilio Therapeutics is not included in the NASDAQ 100 index

Is Xilio Therapeutics in the Dow Jones?

No, Xilio Therapeutics is not included in the Dow Jones index

When was Xilio Therapeutics the previous earnings report?

No data

When does Xilio Therapeutics earnings report?

The next expected earnings date for Xilio Therapeutics is 01 April 2025